Pfizer Signs Big Bang Deal With Aurobindo For Larger Presence in Generics; Biosimilars Next ?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Pfizer has turned its attention to establishing a bigger presence in the U.S. for marketing generic drugs, terming it as an "engine of positive growth." The world's largest drug maker has signed a series of licensing agreements with India's Aurobindo Pharma to acquire rights of 39 generic solid oral dose products and 12 sterile injectable products